- Details
- Alicia Morgans hosts a discussion with Neeraj Agarwal and Petros Grivas about the FDA's approval of sacituzumab govitecan for treating metastatic urothelial carcinoma. Dr. Grivas elaborates on the TROPHY-U-01 trial that led to the drug's approval, emphasizing its efficacy in a heavily pretreated patient population with poor prognostic factors. He notes an overall response rate of 27% and manageabl...
|
- Details
- A transurethral resection of bladder tumor (TURBT), followed by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) is a standard-of-care therapy for muscle-invasive bladder cancer (MIBC). Andrea Necchi, a medical oncologist, and Ewan Gibb a researcher at Decipher Biosciences join Alicia Morgans to discuss a study that expands our understanding of the biology of pembrolizumab-resistant musc...
|
- Details
- Immune checkpoint blockade is a first line therapeutic option in either platinum ineligible patients or carboplatin eligible patients whose tumors also express PD-L1. Patients who are ineligible for cisplatin and progress on immune checkpoint blockade have limited treatment options, and many efforts are underway to expand the therapeutic armamentarium for this disease context. In this conversation...
|
- Details
- Alicia Morgans talks with Andrea Necchi and Laura Marandino. They delve into the PURE-01 study, which focuses on the use of neoadjuvant pembrolizumab in muscle-invasive bladder cancer patients. Dr. Necchi elaborates on the study's primary and secondary endpoints and highlights the role of PET-CT imaging in assessing treatment response. The study finds that PET-CT has limited utility in predicting...
|
- Details
- Platinum-based cytotoxic chemotherapy has been the standard of care for patients with advanced urothelial carcinoma based on improved survival compared to placebo. However, objective response rates are at best 50% and median overall survival is relatively poor at less than 18 months. This has driven the rationale for additional approaches. In first-line (1L) therapy for patients who are not cispla...
|
- Details
- Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a median overall survival (OS) of 7-8 months. Sacituzumab govitecan (Trodelvy) is a TROP-2–directed antibody-drug conjugate with an SN-38 payload that has shown pr...
|
- Details
- Alicia Morgans speaks with Petros Grivas to discuss the intricacies of the SWOG 1806 clinical trial, led by Dr. Parminder Singh. This multi-institutional study aims to evaluate the efficacy of adding atezolizumab, an anti-PD-L1 agent, to chemoradiation treatment in patients with localized muscle-invasive urothelial carcinoma. Dr. Grivas emphasizes the collaborative nature of this "Herculean effort...
|
- Details
- Alicia Morgans is joined by Petros Grivas to discuss a unique study focusing on patients with variant histologies of bladder cancer. The study aims to improve complete response rates by combining chemotherapy with pembrolizumab in a neoadjuvant setting. With only 17 patients, it's a pilot study that tackles the difficulty in finding effective treatments for varying histologies such as squamous cel...
|
- Details
- In this conversation, Alicia Morgans, MD MPH, Neeraj Agarwal, MD, and Petros Grivas, MD, PhD discuss the clinical trial findings from the JAVELIN Bladder 100 trial and how-to treat with chemotherapy followed by avelumab maintenance. They highlight the importance of this to the treatment algorithm of metastatic urothelial carcinoma and highlight a recent publication in Cancer Treatment Reviews on a...
|
- Details
- In February 2021 AstraZeneca announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. In March 2021, Genentech announced the voluntary withdrawals of Tecentriq® (atezolizumab) for the treatment of prior-platinum treated metastatic urothelial carcinoma. Petros Grivas and Alicia Morga...
|
